Purespring Therapeutics Gains FDA Clearance for Clinical Trial
Purespring Therapeutics, a pioneering company in precision nephrology, is excited to announce that it has received FDA clearance for its Investigational New Drug (IND) application for PS-002. This milestone allows the company to initiate a Phase I/II clinical trial focusing on primary IgA nephropathy (IgAN), a rare and chronic kidney condition.
Understanding IgA Nephropathy and PS-002
The lead program from Purespring, PS-002, is designed specifically to address the complement pathway, which is known to play a crucial role in the development of IgAN. In individuals affected by this condition, an abnormal form of immunoglobulin A (IgA) becomes trapped in the kidneys' glomeruli, triggering harmful inflammation and scarring, often leading to kidney failure.
By leveraging precision targeting techniques, PS-002 aims to improve the treatment landscape for patients suffering from IgAN. This approach allows for modulation of complement activation directly at the podocyte level—the specialized cells responsible for maintaining kidney function—setting a new standard for addressing kidney diseases.
Trial Details and Expectations
The approval to commence the Phase I/II clinical trial marks an exciting chapter for Purespring. The company anticipates that patient enrollment will begin in early 2025, with the first participants expected to be treated by the end of that year. The upcoming study will involve local administration of PS-002, focusing on understanding safety and efficacy through various early markers.
During the Phase I part of the trial, safety will be the primary endpoint, while Phase II will delve deeper into both the safety profile and efficacy markers. The ultimate goal of PS-002 is to provide long-lasting benefits with a single treatment.
A Major Milestone for Purespring
CEO Haseeb Ahmad reflected on this momentous achievement, stating, "The IND clearance is a pivotal milestone for Purespring as we embark on a journey to revolutionize kidney care through our innovative drug delivery platform. We are committed to addressing kidney diseases at their root, offering targeted therapeutics that have the potential to modify the course of these conditions for patients."
This positive development in clinical trials follows Purespring's recent recognition by the European Medicines Agency (EMA), which granted orphan drug designation for PS-002. This designation enhances the therapeutic prospects for individuals with IgAN and underscores the urgency and importance of Purespring's work in nephrology.
About Purespring Therapeutics
Established from the groundbreaking research of Professor Moin Saleem, Purespring Therapeutics is dedicated to halting and preventing kidney diseases—one of the least effectively treated areas in modern medicine. With a robust pipeline aimed at addressing both common and unique kidney conditions, Purespring is committed to ethical innovation and scientific integrity.
The company’s current initiatives include several programs targeting complement-mediated kidney diseases and other genetic disorders that compromise kidney function. Leveraging cutting-edge research, Purespring seeks not only to treat but potentially cure many kidney ailments.
Contact Information
For more information, inquiries can be directed to:
Purespring Therapeutics:
Peter Mulcahy
contact@purespringtx.com
+44 (0)20 3855 6324
Also, you may reach out to:
ICR Healthcare:
Amber Fennell, Sarah Elton-Farr
purespring@icrhealthcare.com
Frequently Asked Questions
What is PS-002?
PS-002 is a precision therapeutic developed by Purespring Therapeutics designed to treat primary IgA nephropathy by targeting the complement system in the kidneys.
What conditions does PS-002 target?
PS-002 primarily targets primary IgA nephropathy (IgAN), a chronic autoimmune condition affecting kidney function.
When will the clinical trial for PS-002 begin?
The Phase I/II clinical trial for PS-002 is expected to start enrolling patients in early 2025.
What is the goal of the Phase I/II trial?
The trial aims to assess the safety and efficacy of locally administered PS-002 in treating IgAN.
What recognition has Purespring received for PS-002?
Purespring received orphan drug designation from the EMA for PS-002, emphasizing its potential impact on treating IgAN.
